# Atterx BioTherapeutics, Inc.

> Atterx is a development-stage biopharmaceutical company pursuing bacterial therapies for antibiotic-resistant infections. C-1205 is a catheter-lubricating gel designed to introduce protective E. coli HU2117 into the bladder; GN-4474 targets Gram-negative infections through bacterial conjugation. Its corporate office is in Traverse City, Michigan, with a research facility in Madison, Wisconsin.

- **Founded:** 2001
- **Headquarters:** Traverse City, United States
- **Founders:** Marcin Filutowicz (Co-founder of predecessor ConjuGon; UW–Madison bacteriology professor), Richard Burgess (Co-founder of predecessor ConjuGon; UW–Madison oncology professor)
- **Products:** C-1205, GN-4474
- **Notable:** Founded as ConjuGon following UW–Madison plasmid research., Atterx CEO reported a 2024 IND milestone allowing C-1205 clinical-site selection and enrollment preparations., Reported FDA Fast Track designation for C-1205 on May 1, 2025.

## Products & services

- **C-1205** — Investigational freeze-dried preparation of E. coli HU2117 and a gelling ingredient, reconstituted with water and applied as catheter lubricant to establish protective bladder colonization. Atterx reported FDA Fast Track designation on May 1, 2025.
- **GN-4474** — Investigational conjugation-mediated therapy targeting Gram-negative pathogens; described by the CEO in 2025 as a topical candidate for burn and wound infections. Reported efficacy and resistance experiments are preclinical.

## Achievements

- Founded as ConjuGon following UW–Madison plasmid research.
- Atterx CEO reported a 2024 IND milestone allowing C-1205 clinical-site selection and enrollment preparations.
- Reported FDA Fast Track designation for C-1205 on May 1, 2025.
- Company reports GN-4474 efficacy in animal infection models and no observed resistance emergence in repeated laboratory exposure experiments.

## Latest updates

- **2025-05** — Atterx announced FDA Fast Track designation for C-1205 for CAUTI prevention and stated there was no expanded access available.
- **2025-04** — Michigan Rise announced a March 2025 investment in Atterx through Pre-Seed Fund III; the announcement did not specify the amount.
- **2025-03** — CEO Jim Millar reported the 2024 C-1205 IND milestone and a goal of beginning enrollment in a Phase 1b trial in the third quarter of 2025; this was a target, not confirmation of enrollment.

## Links

- Website: https://www.atterx.com/
- LinkedIn: https://www.linkedin.com/company/atterx-biotherapeutics-inc.

---

Profile page: https://yespress.io/atterx-biotherapeutics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-10-06